Skip to content

Psilocybin: all studies

Page 239 of 439: studies 2,381 to 2,390 of 4,389, newest first. Back to the psilocybin overview

Research

Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.

Neurotrauma reports 2023 Stephanie Karzon Abrams, Brenden Samuel Rabinovitch, Rayyan Zafar et al. 5 citations

Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcomes, less attention is paid on its potential to provide therapeutic benefits across complex medical situations within rehabilitation medicine. Persons with spinal cord injury (SCI) have a high prevalence of treatment-resistant mental health...

Adapting psychedelic medicine for headache and chronic pain disorders.

Expert Review of Neurotherapeutics 2023 Emmanuelle A. D. Schindler, Peter S. Hendricks 5 citations

While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous reports of psychedelics having beneficial effects in other branches of medicine, including for headache disorders and chronic pain. This perspective reviews conventional forms of treatment for headache and other chronic pain disorders and describes...

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.

Neuropsychiatric Disease and Treatment 2023 Kwonmok Ko, Ben Carter, Anthony J. Cleare et al. 26 citations

In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled,...

DOI: 10.2147/ndt.s426193 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Challenging experience Mystical experiences Psilocybin research +2

The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions

Hop and Medicinal Plants December 28, 2022 Vanessa Eveline Vlaic, Andreea Ona

The therapeutic use of the substance psilocin produced by the fungi from the genus named Psilocybe has been an interesting but also controversial topic of discussion among researchers since the 1950s until now. These fungi can synthesize several alkaloids such as psilocybin, which has hallucinogenic properties, but also muscarine, which is a toxic substance that stimulates that part of the...

DOI: 10.15835/hamp14453 (opens in new tab) Psilocybin Hallucinogen Traditional medicine

A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe.

Pharmaceuticals December 28, 2022 Raphaël Serreau, Ammar Amirouche, Amine Benyamina et al. 13 citations

Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various Psilocybe-type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the need to develop simple and...

Mystical experience occasioned by non-medicinal embodied therapy And integration process for mental well-Being

December 22, 2022 Bruce W. Meleski

Expansion of psychoactive hallucinogens in mental health continues to be a major trend. Several psychoactive molecules including psilocybin and MDMA continue to move through the FDA approval process with clinical trials.1 In the meantime, off-label ketamine medically supervised programs and indigenous plant ceremonies continue to expand.2,3 This study explores the potential benefits of High...

The varieties of psychedelic law

Neuropharmacology December 21, 2022 Mason Marks 59 citations

After decades of prohibition, psychedelics are generating intense public and private interest. Scientists are researching the therapeutic properties of these substances, and mounting evidence supports their ability to treat a variety of mental health conditions. Meanwhile, dozens of cities and states are proposing or enacting psychedelics legislation to promote research, increase therapeutic...

DOI: 10.1016/j.neuropharm.2022.109399 (opens in new tab) Ayahuasca Psilocybin Controlled substance regulation Psychedelics policy reform +4

Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.

Scientific Reports December 19, 2022 Grant Jones, Diego Arias, Matthew K. Nock 18 citations

Suicide is one of the leading causes of death amongst adolescents and decades of research have failed to curb suicide rates within this population. There is thus a need to better understand factors that correlate with adolescent suicidal thoughts and behaviors (STBs). MDMA/ecstasy and classic psychedelics represent two areas for exploration, as use of these substances has been associated with...

High time? Psychedelics on cannabis-like fast track to legalization

Canadian Medical Association Journal December 18, 2022 Kevin Zannese 9 citations

Alberta will soon become the first province to regulate psychedelic-assisted therapy. But, as with cannabis, momentum for medical access to psychedelics is outpacing research to guide their use. Earlier this year, Health Canada amended its Special Access Program to allow physicians to request

Novel Perspective of Medicinal Mushroom Cultivations: A Review Case for ‘Magic’ Mushrooms

Agronomy December 15, 2022 Sarana Rose Sommano, Ratchuporn Suksathan, Thanarat Sombat et al. 16 citations

Fruiting bodies, mycelia, or spores in the form of extracts or powder of various medicinal mushrooms are used to prevent, treat, or cure a range of ailments and balance a healthy diet. Medicinal mushrooms are found in several genera of fungi and their fruit bodies, cultured mycelia, and cultured broth contains phytochemical constituents such as triterpenes, lectins, steroids, phenols,...

DOI: 10.3390/agronomy12123185 (opens in new tab) Psilocybin Mushroom Phytochemical Traditional medicine +4